ETC-216 will not be a drug for all the millions of people who suffer from severe coronary artery disease, even if it does eventually get a greenlightfromthe U.S. Food and Drug Administration.
Supporters of the scheme say a decision is needed this year, but it was clear at question time that ministers are a long way from a position where the scheme will getthegreenlight.